Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) insider Mark James Litton sold 16,520 shares of the business’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $12.33, for a total transaction of $203,691.60. Following the sale, the insider now owns 116,452 shares of the company’s stock, valued at approximately $1,435,853.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Alder BioPharmaceuticals, Inc. (ALDR) opened at 11.50 on Friday. The stock’s 50 day moving average is $11.22 and its 200 day moving average is $14.18. The company’s market cap is $778.70 million. Alder BioPharmaceuticals, Inc. has a 52-week low of $8.60 and a 52-week high of $34.30.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.67) by $0.19. The company had revenue of $0.68 million for the quarter. During the same period in the prior year, the company earned ($0.79) EPS. Alder BioPharmaceuticals’s quarterly revenue was up 518.2% on a year-over-year basis. On average, analysts predict that Alder BioPharmaceuticals, Inc. will post ($5.60) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Alder BioPharmaceuticals, Inc. (ALDR) Insider Sells $203,691.60 in Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/21/insider-selling-alder-biopharmaceuticals-inc-aldr-insider-sells-203691-60-in-stock.html.

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp raised its stake in Alder BioPharmaceuticals by 1.0% during the first quarter. State Street Corp now owns 1,777,113 shares of the biopharmaceutical company’s stock worth $36,966,000 after acquiring an additional 18,426 shares in the last quarter. Eagle Asset Management Inc. increased its stake in shares of Alder BioPharmaceuticals by 52.0% in the second quarter. Eagle Asset Management Inc. now owns 1,756,507 shares of the biopharmaceutical company’s stock valued at $20,112,000 after buying an additional 601,242 shares in the last quarter. Redmile Group LLC increased its stake in shares of Alder BioPharmaceuticals by 16.4% in the second quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock valued at $25,463,000 after buying an additional 313,925 shares in the last quarter. Janus Capital Management LLC increased its stake in shares of Alder BioPharmaceuticals by 4.7% in the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company’s stock valued at $107,473,000 after buying an additional 230,044 shares in the last quarter. Finally, ING Groep NV acquired a new stake in shares of Alder BioPharmaceuticals in the second quarter valued at $3,836,000. Hedge funds and other institutional investors own 76.16% of the company’s stock.

Several research firms have weighed in on ALDR. BidaskClub upgraded shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Needham & Company LLC set a $36.00 target price on shares of Alder BioPharmaceuticals and gave the company a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research lowered shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. ValuEngine lowered shares of Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 29th. Finally, Aegis reiterated a “buy” rating and set a $41.00 target price on shares of Alder BioPharmaceuticals in a research note on Wednesday, July 5th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $28.69.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.